Apple Restores Telegram to App Store After Content Policy Violation 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Telegram Restored on Apple App Store After Temporary Removal 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
(4) - EconoTimes)
CAMBRIDGE, Mass., March 30, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on March 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to twelve individuals hired by Sarepta in March 2018. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 42,443 shares of Sarepta's common stock. The options have an exercise price of $74.09 per share. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
